학술논문
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial
Document Type
Article
Author
Source
In: The Lancet Oncology . (The Lancet Oncology, May 2024, 25(5):614-625)
Subject
Language
English
ISSN
14745488
14702045
14702045